Supply of Adenosine Injection (Pharmaceutical Product)

The contract involves the manufacture or supply of Adenosine Injection, a pharmaceutical product essential for cardiac resuscitation, to be delivered in full compliance with both U.S. Food and Drug Administration and Department of Defense standards. This is a subcontract under the Defense Logistics Agency, which operates under the Department of Defense, ensuring the product meets rigorous military and medical specifications for use in emergency medical scenarios. The NAICS code 325412 confirms the activity is within pharmaceutical and medicine manufacturing, and the contract is posted with an effective date of July 16, 2026, signaling a future procurement timeline. The place of performance and exact delivery location are unspecified, but the product will be sourced and distributed to meet DoD requirements across its network. The contract reference number SPE2DX25D8022 with delivery identifier SPE2D926F7386 links to the official DIBBS system, indicating formal award and tracking within the Defense Logistics Agency’s procurement infrastructure. The contract does not specify a set aside or small business designation, and no point of contact details are provided, suggesting the subcontractor is expected to engage directly through official DLA channels for fulfillment and compliance.